At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
IMA-638 is a biologicbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Allergen Challenge
In Brief
A Phase 2 clinical trial evaluating IMA-638 is a biologic for Asthma. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartMar 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedDec 12, 2006
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.6 years ago
Interventions
IMA-638 is a biologicbiological